Can Entrectinib and Lorlatinib be taken together?

Entrectinib (Entrectinib) and Lorlatinib (Lorlatinib) are both targeted therapy drugs, which are ROS1 and ALK kinase inhibitor drugs respectively. Entrectinib is suitable for patients carrying ROS1, NTRK and ALK gene fusions. It can be used to treat lung cancer and other solid tumors that are positive for these gene fusions. Lorlatinib is mainly suitable for patients with advanced non-small cell lung cancer (NSCLC) who haveALK and ROS1 gene fusions. These gene fusions may lead to resistance to traditional ALK inhibitors and ROS1 inhibitors. Based on current research and clinical guidelines, the safety and effectiveness of using these two drugs together cannot be determined. There may be interactions between these two drugs in their mechanisms of action and pharmacokinetics, which may increase the risk of adverse reactions or reduce the efficacy of the drugs.